Gwathmey Inc. is a pre-clinical contract research and consultative biotechnology company providing support to biotechnology companies.The company also performs animal model disease characterization. Services include protocol design, in-vivo large and small animal studies, survival surgery, in-vitro tissues assays, cell biochemistry, molecular biological techniques. The firm also provide animal models.. Gwathmey performs GLP and non-GLP in vitro and in vivo studies and specializes in efficacy testing, pharmacokinetic, biodistribution, and toxicology studies. Expertise includes models of arthritis, cancer, diabetes, heart failure and infectious disease. Mission is to support rapid advancement of promising drugs while quickly eliminating drugs with a poor risk/benefit ratio. Gwathmey, Inc. has leveraged SBIR dollars to create and validate the first human heart failure diagnostic micro-array. The CardionomicsTM detection technology, ready for licensing, can be used to screen patients prior clinical trial enrollment to ensure a higher success rate.
